Home ProductsNatural Nootropics

NSI189 AFA Powder Most Powerful Nootropic Drug Muscle Building

Good quality Body Building Steroids for sales
Good quality Body Building Steroids for sales
have cooperated with biopro for years and I was invited to say something here. most professional packing, highest quality and best service!

—— Alexander Gaus

Biopro is awesome!!!!!My representative is very polite and keep me current with new promotions.Their powders I ordered are giving me very good result!

—— Oleg M

You guys are soooo fast communication and good quality. will definitely get back with more orders.

—— susan Rustiguel

I order with biopro for a long time and can say they are more gentle and attentive seller who you can make an order.

—— Holly Shane

The quality is sooo stable while order from your guys these years,it is amazing quality ,I will never change my source cos it bring me good feedback!!

—— Alex Clinton

I'm Online Chat Now

NSI189 AFA Powder Most Powerful Nootropic Drug Muscle Building

China NSI189 AFA Powder Most Powerful Nootropic Drug Muscle Building supplier
NSI189 AFA Powder Most Powerful Nootropic Drug Muscle Building supplier NSI189 AFA Powder Most Powerful Nootropic Drug Muscle Building supplier

Large Image :  NSI189 AFA Powder Most Powerful Nootropic Drug Muscle Building

Product Details:

Place of Origin: China
Brand Name: Biopro
Certification: GMP/HACCP/ISO
Model Number: NTP-009

Payment & Shipping Terms:

Minimum Order Quantity: 100 Grams
Price: USD1~10 per Gram
Packaging Details: Foil Bag, Drums
Delivery Time: Immediate Shipment
Payment Terms: T/T, Western Union, MoneyGram
Supply Ability: 10 kgs per week
Contact Now
Detailed Product Description
Product Name: NSI - 189 CAS No.: 1270138-40-3
Other Name: NSI189 Classification: Nootropics
Molecular Weight: 366.50 Molecular Formula: C22H30N4O
Purity: 99% Min. Standard: Pharmaceutical Grade

Natural Nootropics NSI189 AFA Powder CAS No. 1270138-40-3 NSI - 189 for bodybuilding

 

  • Description

    NSI-189 is an experimental, novel potential antidepressant that is under investigation by Neuralstem, Inc. for the treatment for major depressive disorder (MDD), as well as for cognitive impairment and neurodegeneration. Research into NSI-189 has been funded by the Defense Advanced Research Projects Agency (DARPA) and the National Institutes of Health (NIH). The mechanism of action of NSI-189 appears to be activation of neurogenesis in the hippocampus and possible enlargement of this structure, but how the drug mediates these effects is unknown and binding studies have so far failed to identify any certain molecular targets for the drug. As stated by Neuralstem, NSI-189 is a "new chemical entity with [a] novel mechanism of action, molecular target yet unknown, but not mediated by SSRI or SNRI or by BDNF release or via any known GPCRs, kinases, or channels." The drug was discovered via high-throughput screening of a library of 10,269 compounds for neurogenic effects in vitro.

     
  • Specification

    Product Name: NSI-189
    Other Name:
    [2-[(3-Methylbutyl)amino]-3-pyridinyl][4-(phenylmethyl)-1-piperazinyl]methanone
    CAS #: 15180-02-6
    Purity: 99% min.
    Molecular Formula:
    C22H30N4O
    Molecular Weight: 366.50
    Structure:

    NSI189 AFA Powder Most Powerful Nootropic Drug Muscle Building
  • Purity

    Our 
    NSI-189 has a purity not less than 99%.
     
  • Application Information

    NSI-189 successfully completed a phase I clinical trial for MDD in 2011, where it was administered to 41 healthy volunteers. A phase Ib clinical trial for treating MDD in 24 patients started in 2012 and completed in July 2014, with results published in December 2015. Neuralstem is now preparing to initiate phase II clinical studies for MDD in the first quarter of 2016, with results expected in the second half of 2017. In the two clinical studies conducted thus far, NSI-189 has shown statistically significant effectiveness in reducing depressive symptoms, has been found to be safe and well-tolerated (with no major adverse effects observed), and has been found to improve cognitive deficits in depressed patients. In addition to MDD, Neuralstem intends to pursue clinical development of NSI-189 for a variety of other neurological conditions, including traumatic brain injury, Alzheimer's disease, post-traumatic stress disorder, stroke, and natural cognitive and memory decline in aging.

  • Reference List of Available Nootropics:
     
    CAS Product Name Other Name
    135463-81-9 Coluracetam BCI-540
    62613-82-5 Oxiracetam ISF 2522
    72432-10-1 Aniracetam Draganon
    59776-89-5 Piracetam  
    72869-16-0 Pramiracetam CI-879
    157115-85-0 Noopept GVS-111
    15180-02-6 Amfonelic Acid AFA
    314728-85-3 Sunifiram DM-235
    1270138-40-3 NSI-189 NSI189
    51352-87-5 PRL-8-53  
    314728-85-3 Unifiram DM-232
    22503-72-6 IDRA-21  

  •  

Contact Details
Biopro Chemicals Co., Ltd.

Contact Person: Mr. Johnny

Send your inquiry directly to us (0 / 3000)